EFFICACY OF RUXOLITINIB IN MYELOID NEOPLASMS WITH PCM1-JAK2 FUSION GENE

被引:0
|
作者
Casetti, I. C. [1 ]
Milosevic, J. D. [2 ]
Rumi, E. [3 ]
Selleslag, D. [4 ]
Lierman, E. [5 ]
Pietra, D. [3 ]
Cavalloni, C. [1 ]
Bellini, M. [1 ]
Milanesi, C. [3 ]
Astori, C. [3 ]
Kralovics, R. [2 ]
Vandenberghe, P. [5 ]
Cazzola, M. [1 ,3 ]
机构
[1] IRCCS Policlin San Matteo, Dept Mol Med, Pavia, Italy
[2] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria
[3] IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[4] Acad Hosp St Jan, Dept Hematol, Brugge, Belgium
[5] Katholieke Univ Leuven, Univ Hosp Leuven, Ctr Human Genet, Leuven, Belgium
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
E1342
引用
收藏
页码:537 / 538
页数:2
相关论文
共 50 条
  • [21] Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
    Simone Romagnoli
    Niccolò Bartalucci
    Francesca Gesullo
    Manjola Balliu
    Stefania Bonifacio
    Anair Graciela Lema Fernandez
    Francesco Mannelli
    Davide Bolognini
    Elisabetta Pelo
    Cristina Mecucci
    Paola Guglielmelli
    Alessandro Maria Vannucchi
    Biomarker Research, 9
  • [22] Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia
    Rizzuto, Giuliana
    Leoncin, Matteo
    Imbergamo, Silvia
    Taurino, Daniela
    Mico, Maria Caterina
    Tosi, Manuela
    Michelato, Anna
    Buklijas, Ksenija
    Spinelli, Orietta
    Lussana, Federico
    Lessi, Federica
    Pizzi, Marco
    Bonaldi, Laura
    Binotto, Gianni
    Rambaldi, Alessandro
    Gurrieri, Carmela
    CLINICAL CASE REPORTS, 2022, 10 (01):
  • [23] Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2
    Baer, Constance
    Muehlbacher, Verena
    Kern, Wolfgang
    Haferlach, Claudia
    Haferlach, Torsten
    HAEMATOLOGICA, 2018, 103 (08) : E348 - E350
  • [24] PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature
    Kaplan, Henry G.
    Jin, Ruyun
    Bifulco, Carlo B.
    Scanlan, James M.
    Corwin, David R.
    ONCOLOGIST, 2022, 27 (08): : E661 - E670
  • [25] Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
    Sun, Yingxin
    Cai, Yifeng
    Chen, Jia
    Cen, Jiannong
    Zhu, Mingqing
    Pan, Jinlan
    Wu, Depei
    Sun, Aining
    Chen, Suning
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma
    J Adélaïde
    C Pérot
    V Gelsi-Boyer
    C Pautas
    A Murati
    C Copie-Bergman
    M Imbert
    M Chaffanet
    D Birnbaum
    M-J Mozziconacci
    Leukemia, 2006, 20 : 536 - 537
  • [27] The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
    Bousquet, M
    Quelen, C
    De Mas, V
    Duchayne, E
    Roquefeuil, B
    Delsol, G
    Laurent, G
    Dastugue, N
    Brousset, P
    ONCOGENE, 2005, 24 (48) : 7248 - 7252
  • [28] Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA
    Salehi, Sajad
    Astle, John M.
    Sadigh, Sam
    Lake, Jonathan
    Aikawa, Vania
    Tang, Guilin
    Wang, Sa A.
    Bagg, Adam
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2299 - 2303
  • [29] Comprehensive Genetic Characterization of 63 Myeloid/Lymphoid Neoplasms Associated with Eosinophilia and Rearrangement of PDGFR-α, PDGFR-β, FGFR1 or PCM1-JAK2
    Baer, Constance Regina
    Muehlbacher, Verena
    Kern, Wolfgang
    Haferlach, Claudia
    Haferlach, Torsten
    BLOOD, 2017, 130
  • [30] The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
    Marina Bousquet
    Cathy Quelen
    Véronique De Mas
    Eliane Duchayne
    Blandine Roquefeuil
    Georges Delsol
    Guy Laurent
    Nicole Dastugue
    Pierre Brousset
    Oncogene, 2005, 24 : 7248 - 7252